Sign in
Taking people in United StatesPhase 2

Numbing Cream Tested for Pain During Skin Cancer Lymph Node Mapping

Tests a numbing cream to ease pain from scan injections in skin cancer.

Key facts

Who runs it
Ohio State University Comprehensive Cancer Center
Where
Columbus, United StatesSee the site
Trial code
Registry title
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
19 Dec 2023
Planned end
31 Oct 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eutectic Mixture of Local Anesthetics
  • Placebo Administration
  • Questionnaire Administration
Record updated
10 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a skin cancer who are having a lymph node mapping test with Technetium 99 injections. It tests whether EMLA numbing cream eases the pain of the injections.

Age
18 to 99 years
Sex
Men and women can both join.
Disease stage
Skin cancer confirmed under the microscope (melanoma, Merkel cell carcinoma, squamous cell carcinoma or another skin cancer) where lymph node mapping and a sentinel lymph node biopsy has been advised.

Main reasons for not taking part

  • Allergy or intolerance to EMLA cream, lidocaine, prilocaine or another local anesthetic
  • Allergy to adhesive
  • Cannot have the Tc99 injection for lymph node mapping
  • Pregnancy
  • Chronic pain, or narcotic pain medicine in the 7 days before the procedure

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Biologic males or females
  • 18 - 99 years of age
  • Histologically confirmed cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or other cutaneous malignancy for which lymphoscintigraphy and sentinel lymph node biopsy has been recommended

Who cannot take part

  • Known allergy or intolerance to EMLA cream, lidocaine, prilocaine, or any other local anesthetic
  • History of adhesive allergy
  • Participants with chronic pain as defined by the Centers for Disease Control and Prevention (CDC):"pain lasting 3 months or more that can be caused by a disease or condition, injury, medical treatment, or unknown reason" excluding those with stable co-morbid conditions such as peripheral neuropathy, fibromyalgia, arthritis, and cancer-related pain who do not require narcotics. Patients who require narcotics at any time within the 7-day period leading up to the procedure
  • Contraindication to Tc99 injection for sentinel lymph node mapping
  • Incarcerated patients
  • Patients incapable of independently providing consent
  • Mucosal or genital lymphoscintigraphy site
  • Pregnancy
  • Participant self-declared or Ohio State University (OSU) medical chart listing chronic pain as a pre-existing diagnosis

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Carlo M. Contreras, MDTaking people

About the trial

What the trial wants to find out

This phase II trial tests how well EMLA topical cream works in treating pain in patients with skin cancers receiving Technetium 99 injections for a lymphoscintigraphy mapping procedure. A lymphoscintigraphy mapping procedure is used to find the main or lead lymph node (tissue that fight infection) so it can be removed and checked for tumor cells. Using lymphoscintigraphy to highlight and then surgically remove lymph nodes is standard way to treat skin cancer for many patients. The Technetium 99 injections used for lymphoscintigraphy can be briefly painful due to the sensitivity of the nerve endings in the skin. The EMLA topical cream, which contains a numbing medicine to block pain from nerve endings, has been studied in breast cancer patients with a difference in pain reported, but this is the first time it has been studied in patients undergoing lymphoscintigraphy for skin cancer. This study may help researchers learn whether the use of EMLA cream may improve the associated pain at the time of the lymphoscintigraphy procedure.

The 2 groups in the trial

  • Cohort 2 (placebo cream)Placebo, for comparison

    Patients apply placebo cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.

    Treatment: Placebo Administration and Questionnaire Administration

  • Cohort 1 (EMLA cream)Treatment being tested

    Patients apply EMLA cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.

    Treatment: Eutectic Mixture of Local Anesthetics and Questionnaire Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Investigating the Use of EMLA Topical Cream for Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Cutaneous Cancers
Plain-language title
Numbing Cream Tested for Pain During Skin Cancer Lymph Node MappingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06223659, who can take part
Record updated
10 March 2026